The screening schedule nobody gave you
There is a published maintenance schedule for the metabolic side of PMOS (PCOS) — what gets measured, and how often. It runs through 254 recommendations, and almost nobody is handed it. Here is what it asks for, and the four questions that turn it into something you can check.
Before anything else
This is a description of what published guidance says clinicians should be checking. It is not a diagnosis, not a lab order, and not a reason to start or stop anything. Take it to a clinician who can look at your actual numbers.
There is a version of PMOS (PCOS) care that most women never receive, and it is not exotic. It is written down. It has been through a fourteen-year consensus process, it runs to 254 recommendations and practice points, and it includes a schedule — how often the metabolic parts of you are supposed to be measured, and starting when.
Almost nobody is handed that schedule. What most women are handed is a prescription for the pill, an instruction to lose weight, and a follow-up in a year if something goes wrong.
What the schedule actually says
A review published in The Journal of Clinical Investigation in June sets it out plainly. At diagnosis, the assessment is supposed to be comprehensive: a lipid profile, blood pressure, and glucose tolerance testing. After that, it does not stop. Blood pressure should be re-checked at least annually. Glucose should be re-checked every one to two years, and more often if other risk factors are present.
Annually. Every one to two years. Those are not heroic intervals. They are the ordinary maintenance schedule for a condition in which the same review puts insulin resistance at up to 70% of patients, and where insulin resistance is not a side plot — it drives the androgen excess that produces the symptoms most women came in about.
Insulin resistance in up to 70% of patients is not a complication of the condition. For most women it is the engine of it.
That is also, incidentally, why the name changed in May. Polyendocrine metabolic ovarian syndrome puts the metabolic part in the title, where the old name buried it behind cysts that are not really cysts.
Where GLP-1s sit in it
The same review is measured about this, and we will be too. GLP-1 receptor agonists show promising results in PMOS — improving reproductive function and reducing metabolic complications — with the improvement understood as running downstream of better insulin sensitivity and weight, not as a direct treatment for the syndrome. Metformin remains the long-standing standard for the insulin dysfunction itself. No GLP-1 is FDA-approved specifically for PMOS.
The review is also clear about a limit we have written about before: safety data in pregnancy remain limited, and current guidance recommends stopping when you are trying to conceive. If that is on your horizon, the consensus guidance published in July goes into it properly.
The question this turns into
If a schedule exists, then "does my provider follow it?" is an answerable question rather than a feeling. That is a better position to be in than most of PMOS care allows.
So: at intake, did anyone order a lipid panel, a blood pressure reading, and a glucose tolerance test — or did the intake consist of a height, a weight, and a card number? Is there a date in the calendar for re-checking glucose, or does the re-check happen if you ask? Who reads the result when it comes back, and where does it go?
We built the Care Standard around questions of exactly this shape. A service that will prescribe a GLP-1 and never look at a metabolic panel is not doing PMOS care. It may be doing something useful, and it may be doing it cheaply, but it is a different service — and it is frequently sold at the same price as the other kind. The first row on every scorecard is there to separate them.
A note on what this is not
None of this means a lean intake is negligent, or that a provider who does not run labs is doing something wrong. Plenty of platforms are explicit that they are a medication channel and not a metabolic clinic, and for a woman whose primary care already handles her screening, that can be a perfectly sensible split — cheaper, faster, and no duplication.
The failure mode is not choosing the lean version. It is choosing it without knowing that you did, and assuming the screening is happening somewhere because surely someone is doing it. In a fragmented system, "surely someone" is how a fasting glucose goes six years without being drawn.
Ask who owns your numbers. If the answer is nobody, the answer is you — and knowing that is worth more than the schedule itself.
The honest disclaimer. This is general information from the women who write Selene — not medical advice, not a diagnosis, and not a recommendation about any medication. Screening intervals described here are drawn from published clinical guidance and are not a substitute for a clinician deciding what is right for you. No GLP-1 is FDA-approved specifically for PMOS (PCOS), and GLP-1 medications are not a treatment for endometriosis. Selene is editorial: we do not prescribe, sell, or dispense anything.
Sources. Chan JL, Masini I, Pisarska MD, "Polyendocrine metabolic ovarian syndrome (PMOS)/polycystic ovary syndrome (PCOS): current and future trends," The Journal of Clinical Investigation, 136(12), 15 June 2026; International Evidence-based Guideline for the Assessment and Management of PMOS (254 recommendations and practice points), as summarised by the American Society for Reproductive Medicine; "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process," The Lancet, 12 May 2026.